BioTuesdays: Cantor says Sucampo weakness overdone
Cantor Fitzgerald analyst Irina Rivkind says shares of Sucampo Pharmaceuticals (NASDAQ:SCMP) are trading off on a recent downgrade of competitor Ironwood Pharmaceuticals (NASDAQ:IRWD), reflecting news that Ironwood’s Linzess will be priced below Sucampo’s Amitiza.
A Cowen & Co. analyst downgraded shares of Ironwood on Monday, citing the company’s growing expenses and disappointing early sales of its bowel drug Linzess.
Ms. Rivkind writes that the Linzess pricing strategy was the subject of a recent BioCentury article that highlighted Ironwood’s attempts to gain improved reimbursement for Linzess by entering the market at a lower price than Amitiza on launch last December.
“We note that there is nothing new in this BioCentury article........